Key Takeaways DNLI outlined a 2026 roadmap as it prepares for potential FDA approval and launch of tividenofusp alfa.FDA extended the BLA review for tividenofusp alfa to April 5, 2026, after updated clinical pharmacology dataSeveral programs target 2026 readouts, including DNL126 data and BIIB122 LUMA results.Denali Therapeutics Inc. (DNLI) recently outlined its roadmap for 2026 across its portfolio of investigational therapies for neurodegenerative diseases, lysosomal storage disorders and other serious di ...